Biotech Newcomer Alumis Makes Nasdaq Debut with $250 Million IPO Haul
On June 28, Alumis, a cutting-edge biotech firm, successfully launched its initial public offering (IPO) on the Nasdaq exchange, securing a substantial $250 million in funding. The company’s impressive debut saw 13.125 million shares change hands at $16 per share, despite initially scaling back its offering. This significant influx of capital will likely propel Alumis forward as it continues to advance its innovative immunology treatments through late-stage clinical trials.
Leave a Reply